loading...
tooltip
Blogs
  • Board
  • Businesses
  • People
  • Products
  • Videos
  • Blogs
  • Audios
  • Images
  • Coupons
  • Deals
  • Maps
{{SelectedCountryName}}
  • {{country.Country1}}
{{SelectedStateName}}
  • {{state.State1}}
{{SelectedCountyName}}
  • {{county.CountyName}}
{{SelectedCityName}}
  • {{city.City}}
Blogs
  • Board
  • Businesses
  • People
  • Products
  • Videos
  • Blogs
  • Audios
  • Images
  • Coupons
  • Deals
  • Maps
Back     
  •  
     

Vitae Pharmaceuticals (VTAE) Is Alzheimer's Disease Preventable?, KLA-Tencor (KLAC) Leveraged Recapitalization Strategy

Karl Stemtrowsky
Posted By:
Location:
Storeboard City:
Status: Pharmacyclics Inc. (PCYC) reported trial results of the first Phase III study (RESONATE, PCYC-1112-CA), a head-to-head comparison of IMBRUVICA(R) (ibrutinib) versus ofatumumab in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (a slow-growing lymphoma in which too many immature white blood cells cause lymph nodes to become larger than normal).According to PCYC, patients receiving IMBRUVICA realized a significant improvement in progression free survival, overall survival and overall response rate as compared to patients receiving ofatumumab. http://finance.crwe-pr.com/2014/06/01/trials-positive-data-advaxis-nasdaqadxs-cervical-cancer-abbvie-nyseabbv-and-pharmacyclics-nasdaqpcyc-chronic-lymphoma-leukemia/
Spacer
3,043 Days Ago